Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495195 · ClinicalTrials.gov registry record · Phase 2
Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
A Phase 2 study of Cocaine Use Disorders, sponsored by Midwest Biomedical Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01495195: Completed Phase 2 study of Cocaine Use Disorders, sponsored by Midwest Biomedical Research Foundation.
NCT01495195 is a Phase 2 study of Cocaine Use Disorders that has completed, run by Midwest Biomedical Research Foundation. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01495195, a Phase 2 study of Cocaine Use Disorders, has completed, sponsored by Midwest Biomedical Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Disease. Both of these medications can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if combined treatment with donepezil and selegiline can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.
Primary Outcome
Participants will make a series of choices between vouchers with an ascending monetary value and intravenous injections of cocaine
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selegiline
- DRUG High-dose donepezil
- DRUG Low-dose donepezil
Study Locations (1)
Missouri
- Kansas City VA Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01495195 record still lists
NCT01495195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cocaine Use Disorders appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01495195 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01495195 about?
NCT01495195 is a clinical study titled "Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior". No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Di...
What is the current status of trial NCT01495195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-02. Estimated completion is 2013-05.
What conditions does trial NCT01495195 study?
This clinical trial studies the following conditions: Cocaine Use Disorders.
What interventions are being tested in trial NCT01495195?
The interventions under investigation include: Placebo (DRUG), Selegiline (DRUG), High-dose donepezil (DRUG), Low-dose donepezil (DRUG).
Who is sponsoring clinical trial NCT01495195?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01495195 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01495195's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia